Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification

George J. Netto,Mahul B. Amin, Eva M. Comperat,Anthony J. Gill,Arndt Hartmann,Holger Moch,Santosh Menon,Maria R. Raspollini,Mark A. Rubin,John R. Srigley,Puay Hoon Tan,Satish K. Tickoo,Toyonori Tsuzuki,Samra Turajlic,Ian Cree,Daniel M. Berney

EUROPEAN UROLOGY（2023）

Cited 23|Views2

No score

Abstract

We present the rationale for keeping the “cancer” label for grade group 1 (GG1) prostate cancer. Maintaining GG1 as the lowest grade outweighs the potential benefits that a benign designation may bring. Patient and surgeon education on the vital role of active surveillance for GG1 cancers and avoidance of overtreatment should be the focus rather than such a drastic change in nomenclature.

Translated text

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined